Clinical trial · no report yet · Phase 3
TORCHLIGHT
Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment
- NCT04085276 ↗
- Completed
- Shanghai Junshi Bioscience Co., Ltd.
- 6 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 3 | |
| Podcasts | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-Blind, Multicenter, Phase III Study of Toripalimab(JS001) in Combination With Nab-Paclitaxel Versus Placebo Plus Nab-Paclitaxel for Patients With Metastatic or Recurrent Triple-Negative Breast Cancer With or Without Systemic Treatment (TORCHLIGHT)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- JS001; Nab-Paclitaxel; Placebo; Nab-Paclitaxel
- Arms
- JS001 Plus Nab-Paclitaxel · Experimental
- Placebo Plus Nab-Paclitaxel · Placebo comparator
- Enrollment
- 531
- Primary outcomes
- Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Intend to Treat patients.
- PFS assessed by BICR using RECIST v1.1 in PD-L1 positive patients
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Start
- Dec 21, 2018
- Primary completion
- Dec 31, 2024
- Results posted
- No
- Registry record
- NCT04085276 · updated Apr 16, 2026